Finance

Lists
8LY:FRA
Oncozenge AB
€0.33
-9.97%
(-0.037) 1D
Sep 4, 10:00:00 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for 8LY...
Open
€0.33
High
€0.33
Low
€0.33
Mkt. cap
92.85M
Volume
0.00
52-wk high
€0.62
52-wk low
€0.33
No. of employees
1
Open
€0.33
High
€0.33
Low
€0.33
Mkt. cap
92.85M
Volume
0.00
52-wk high
€0.62
52-wk low
€0.33
No. of employees
1
About Oncozenge AB
CEOPaul de Potocki
Employees1
Founded2020
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in SEK
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in SEK
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
2.00K
1.00K
-
5.96M
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.48M
9.75M
6.80M
11.25M
Operating expense
3.48M
9.75M
6.80M
11.40M
Total operating expenses
3.48M
9.75M
6.80M
11.40M
Operating income
-3.48M
-9.75M
-6.80M
-5.44M
Other non operating income
-
-
-
-
EBT including unusual items
-3.49M
-9.89M
-7.13M
-5.67M
EBT excluding unusual items
-3.49M
-9.89M
-7.13M
-5.67M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
2.00K
-
2.00K
150.00K
Net income
-3.49M
-9.89M
-7.13M
-5.67M
Net profit margin
-174,550.00%
-988,600.00%
-
-95.04%
Earnings per share
-
-
-
-
Interest and investment income
1.00K
15.00K
-
-
Interest expense
-13.00K
-154.00K
-330.00K
-226.00K
Net interest expenses
-12.00K
-139.00K
-330.00K
-226.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
-
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google apps